AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02769000 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 10 GY in 5 daily fractions
Description: Subjects 1-15 10 GY in 5 daily fractions
Study NCT02769000 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 20 GY in 10 daily fractions
Description: Subjects 16-30 20 GY in 10 daily fractions
Study NCT00811265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate MRgFUS for prostate cancer
Description: Simulated use of ExAblate MRgFUS system
Study NCT02139085 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GSV Electrocoagulation
Description: The energy source will be the Electrosurgical Generator (FX-Valley Lab; USA) and the GSV thermo ablation will be performed with 60 Watts per 10 seconds. The catheter and electrocoagulation device head will be pulled back in increments of 2 cm also to overlap the treatment sites.
Study NCT02139085 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GSV Radiofrequency
Description: The second generation RF device (Closure FAST; Covidien, USA) will be used. The treatment component of the device is 7 cm in length and works with a segmental pullback protocol. Once the catheter is in position, activation of the generator delivers 20- seconds cycles of energy to the catheter tip, which heats the vein wall to 120 o C.
Study NCT01789008 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Determination of Advanced Fibrosis in Alcoholic Liver Disease
Study NCT01789008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Determination of Advanced Fibrosis in Alcoholic Liver Disease
Study NCT01332513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR1)
Description: Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.
Study NCT01332513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR2)
Description: Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.
Study NCT01332513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR3)
Description: Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.
Study NCT01332513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR4)
Description: Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.
Study NCT01332513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (MR5)
Description: Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.
Study NCT01332513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational Medicinal Product (IR)
Description: Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.
Study NCT00821522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: Three 5-minute intervals of leg ischemia induced by tourniquet inflation, prior to initiation of cardiopulmonary bypass.
Study NCT01829295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: For the first two weeks, an introductory dose of 500 mg twice a day (BID) orally. After two weeks, the dose will be increased to 1.5 g BID.
Study NCT01829295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
Study NCT01829295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
Study NCT03182686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of Ampion
Description: 4 mL injection of Ampion
Study NCT03182686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 mL Injection of Placebo
Description: 4 mL Injection of Placebo
Study NCT01213719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 20g/d throughout 10 days
Study NCT01213719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: betaine
Description: 2g/d throughout 10 days
Study NCT01213719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dextrose
Description: dextrose (placebo), 20 g/d throughout 10 days
Study NCT01213719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: creatine plus betaine
Description: creatine (20g/d) plus betaine (2g/d) throughout 10 days
Study NCT00817466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racemic adrenaline
Description: For inhalation.~Dosing (as in previous study):~1) 0,1ml\<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml >10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number.
Study NCT00817466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: 2ml NaCl 9mg/ml.
Study NCT01866683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 month respiratory training
Description: Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika
Study NCT01866683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1 month waiting period
Description: waiting or detraining period
Study NCT01154127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: 50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
Study NCT01472692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Description: 80mg PO daily for 8 weeks
Study NCT03308097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP Mobile Messaging Intervention
Description: See group description
Study NCT03308097 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: See group description
Study NCT00789854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR
Description: 300 mg once daily (od)
Study NCT01154127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
Study NCT00789854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium carbonate
Description: 900 mg once daily (od)
Study NCT00789854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI/Venlafaxine
Description: SSRI - doses within label, Venlafaxine dose up to 225 mg/day
Study NCT03104140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: After fluid resuscitation, patients will receive :1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
Study NCT03104140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental
Description: After fluid resuscitation, patients will receive :2 mg/Kg Thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
Study NCT04426058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP
Description: Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml
Study NCT04426058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Illica
Description: Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml
Study NCT03032926 — intervention group
Intervention type: BEHAVIORAL
Intervention: Open Trial
Description: Behavioral Intervention
Study NCT04145752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nurse-led femoral nerve block
Description: The nurse perform a femoral nerve block in the emergency department in patients diagnosed with a hip fracture (x-ray)
Study NCT04145752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-led femoral nerve block
Description: The nurse perform a femoral nerve block in the emergency department in patients diagnosed with a hip fracture (x-ray)
Study NCT01940237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Interpersonal psychotherapy in the treatment of major depressive disorder.
Study NCT02717338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competence
Description: Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
Study NCT02389309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study NCT02389309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study NCT02389309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02389309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT02307942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric banding
Description: The bariatric procedure is a gastric banding under general anesthesia with all the centres using the same surgical procedure (harmonized by group meetings). The laparoscopic surgical procedure has been described. The ERAS protocol will be applied in each centre. The inflation of the band will follow the procedures described by 0'Brien. The patients will attend a group education session before surgery, during which the eating behaviour with a band will be explained and practiced. Then after surgery, the routine procedure is applied.
Study NCT04262999 — intervention group
Intervention type: OTHER
Intervention: effect of sodium valproate on alveolar bone level
Description: Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate drug therapy.
Study NCT04262999 — intervention group
Intervention type: OTHER
Intervention: effect of levetiracetam on alveolar bone level
Description: Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on levetiracetam drug therapy.
Study NCT04262999 — intervention group
Intervention type: OTHER
Intervention: effect of sodium valproate+levetiracetam on alveolar bone level
Description: Comparative evaluation of bone mineral density and levels of marginal alveolar bone in patients with epilepsy on sodium valproate+levetiracetam drug therapy.Comparative evaluation of periodontal parameters in all the patients who are on sodium valproate+ levetiracetam drug therapy.
Study NCT04262999 — intervention group
Intervention type: OTHER
Intervention: control group
Description: Control group individuals will be systemically healthy.
Study NCT02717338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy
Description: Participants will be assigned to receive a brief telephone interview that we have developed that encourages blood donors to reflect upon their unique motivations for giving and how the act of donating is consistent with their broader life goals and values.
Study NCT02717338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relatedness
Description: Participants will be asked to join a closed Facebook group for one month. The group encourages participants to discuss their experiences with blood donation, including such things as posting images of their donations and/or reasons for donating. Posts will be designed to encourage social interaction around donation experiences, identity formation and group affiliation.
Study NCT01581762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided FNA
Description: EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
Study NCT01581762 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: EUS-guided FNA
Description: EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
Study NCT00267293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Given for fever control 15mg/kg
Study NCT00267293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Given for fever control 10 mg/kg
Study NCT00267293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Given for fever control 10 mg/kg
Study NCT00700869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: mechanical ventilation
Study NCT03755700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: As a gel capsule of vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention
Study NCT03755700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: As an effervescent tablets of NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention
Study NCT03755700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group
Study NCT03755700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group
Study NCT03755700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group
Study NCT03755700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group
Study NCT03755700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
Study NCT03755700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
Study NCT02881463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutical exercises
Description: Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
Study NCT02932384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention-Passport and Peer Mentor
Description: In addition to the passport and incentives described below for the control condition, participants assigned to the intervention will select a peer mentor trained in motivational interviewing. The mentor will help guide the participant to complete passport items and address priorities. Participants will also be incentivized for regular meetings with his peer mentor.
Study NCT02932384 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control-Passport Only
Description: A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.~Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete.
Study NCT02932384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control-Passport Only
Description: A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.~Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete.
Study NCT02079922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
Study NCT02079922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
Study NCT02079922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06678552
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
Study NCT02079922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
Study NCT01866410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01866410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT00971685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone
Description: RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
Study NCT01814995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition/Physical Activity Intervention
Description: Please see Arm description.
Study NCT04562298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-M23 cells
Description: Prior to infusion of LCAR-M23, subjects will receive a premedication regimen (intravenous infusion of cyclophosphamide 300 mg/m2 and fludarabine 30 mg/m2 once daily for 3 days; fludarabine dose reduction to 25 mg/m2 and cyclophosphamide to 250 mg/m2 are allowed if the subject' s creatinine clearance is 50-70 mL/min/1.73 m2). A single dose, single Infusion of LCAR-M23 is scheduled 5 to 7 days after the initiation of the premedication regimen.
Study NCT03121469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Papillon +TM
Description: Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
Study NCT04153201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine 200 mg daily for patients weighing \< 60 kg, hydroxychloroquine 400 mg daily for patients weighing >= 60 kg
Study NCT02272881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical reconstruction
Description: Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.